What case management recommendations should be provided for a 60-year-old male with schizoaffective disorder (bipolar type), recurrent major depressive disorder, hypertension, chronic kidney disease, heart failure, anemia, protein‑calorie malnutrition, chronic pain, nicotine dependence, anxiety, opioid abuse, and recent mosquito bites?

Case Management Recommendations for Complex Psychiatric and Medical Comorbidities

This patient requires integrated multidisciplinary case management with immediate focus on psychiatric stabilization, cardiometabolic monitoring, substance use intervention, and nutritional rehabilitation, coordinated through a single case manager who ensures treatment adherence and prevents fragmented care.

Immediate Priorities

1. Psychiatric Case Management Structure

Establish intensive case management with a designated medical professional conducting home visits, workplace monitoring, and family engagement at intervals tailored to clinical stability 1, 2. For patients with schizoaffective disorder and multiple comorbidities like this one, case management has demonstrated:

• Improved treatment adherence
• Reduced hospitalizations
• Enhanced functional recovery
• Decreased family burden 2

The case manager should coordinate all care through a single point of contact, preventing the fragmented care that increases unplanned admissions in patients with multiple chronic conditions 3.

2. Mental Health Baseline Assessment and Monitoring

Conduct formal depression screening immediately using the two-question screen: "During the past 2 weeks have you been bothered by feeling down, depressed, or hopeless?" and "During the past 2 weeks have you been bothered by little interest or pleasure in doing things?" 1. Given his diagnosis of recurrent major depressive disorder and history of suicidal ideation, if either answer is affirmative, follow with PHQ-9 screening 1.

Critical monitoring requirements:

• PHQ-9 scores ≥10 require psychiatric follow-up (88% sensitivity and specificity for major depression) 1
• Screen for neurocognitive disorders given chronic kidney disease and cardiovascular disease 1
• Document baseline mental health status including coping skills, substance use patterns, and suicidal ideation 1

3. Cardiometabolic Treatment Gap Closure

This patient has a dangerous cardiometabolic treatment gap that requires immediate attention. With hypertensive heart disease, heart failure, chronic kidney disease, and current BP 140/76, his cardiovascular medications appear inadequate 4.

Specific actions needed:

• Blood pressure control: Current BP 140/76 on amlodipine 10mg and carvedilol 3.125mg suggests undertitration. Carvedilol dose is subtherapeutic for heart failure (typical target 25-50mg BID). Coordinate with cardiology for uptitration 4
• Lipid management: Fenofibrate 48mg suggests dyslipidemia, but no statin is listed. Assess fasting lipid panel and consider statin initiation given cardiovascular disease 4
• Metabolic monitoring: Screen for diabetes/prediabetes with HbA1c and fasting glucose, especially given quetiapine use and protein-calorie malnutrition 4
• Anemia workup: Unspecified anemia with CKD requires evaluation for iron deficiency, B12/folate status (already supplementing), and potential EPO therapy 4

Between 29.5-35.3% of psychiatric patients have elevated blood pressure without treatment, and 47.9-50.7% have hypercholesterolemia without statins 4. This patient likely falls into this treatment gap.

4. Chronic Pain Management

For his right leg pain and chronic pain, avoid opioid escalation given documented opioid abuse history 1.

Recommended pain management algorithm:

1. First-line: Gabapentin titrated to 2400mg/day in divided doses for neuropathic pain (improves sleep, which addresses his insomnia) 1
2. Adjunctive: Continue acetaminophen 500mg q6h PRN, but monitor total daily dose ≤4g (can increase systolic BP in hypertension) 5
3. Topical agents: Consider capsaicin cream or lidocaine patches for localized pain 1
4. Physical therapy: Refer for graded exercise and mobility improvement given "other reduced mobility" diagnosis 6
5. Avoid: NSAIDs (contraindicated with CKD, heart failure, and hypertension) 5

If gabapentin inadequate after adequate trial, consider duloxetine (SNRI) but monitor blood pressure closely, or low-dose tricyclic antidepressant with cardiac monitoring 1.

5. Substance Use Intervention

Address opioid abuse and nicotine dependence through integrated treatment 7.

Opioid abuse management:

• Assess current opioid use patterns and consider buprenorphine/naloxone for medication-assisted treatment if active use 1
• Coordinate pain management to avoid prescription opioid diversion
• Screen for other substance use (alcohol, marijuana) that could destabilize psychiatric symptoms 8

Nicotine dependence:

• Offer varenicline or bupropion as first-line pharmacotherapy 9
• Nicotine replacement therapy (patches, gum) as alternative
• Smoking cessation is critical given cardiovascular disease and worsens prognosis in schizoaffective disorder 9
• Atypical antipsychotics (quetiapine) have better tolerability profile for smoking cessation 9

6. Nutritional Rehabilitation

Protein-calorie malnutrition requires aggressive intervention:

• Refer to dietitian for nutritional assessment and meal planning
• Consider mirtazapine's appetite-stimulating effects as beneficial side effect 5
• Monitor weight and albumin levels monthly
• Address food insecurity through social work referral if needed

7. Medication Optimization and Monitoring

Current psychiatric regimen review:

• Quetiapine 200mg QHS: Appropriate for schizoaffective disorder, bipolar type. Continue with metabolic monitoring (weight, glucose, lipids every 3 months) 7
• Lamotrigine 25mg daily: Subtherapeutic dose for bipolar maintenance. Typical target 200-400mg/day. Slow titration needed (increase by 25mg every 2 weeks) to prevent Stevens-Johnson syndrome 7
• Mirtazapine 15mg daily: Appropriate for depression and insomnia. Safe in cardiovascular disease. Continue 5
• Hydroxyzine 25mg TID: For anxiety. Monitor for anticholinergic burden and falls risk given cardiovascular medications 5

Maintenance treatment: Continue mood stabilizer (lamotrigine) for at least 2 years after last bipolar episode, with specialist consultation for longer-term decisions 7.

8. Psychosocial Interventions

Implement structured psychosocial support 1, 7:

• Psychoeducation: Routinely offer to patient and family about schizoaffective disorder, medication adherence, early warning signs of relapse 7
• Cognitive behavioral therapy: Consider referral if available for chronic pain, anxiety, and depression management 1
• Social skills training: To address reduced mobility and social functioning 7
• Supported employment: Facilitate return to work given recent temporary lawn mowing job. Coordinate with vocational rehabilitation 7

9. Care Coordination and Communication

Establish clear communication pathways 1, 3:

• Schedule longer appointment times for comprehensive review
• Document all diagnoses, medications, and treatment plans in EMR accessible to all providers 3
• Coordinate with cardiology, nephrology, pain management, and psychiatry
• Involve family/caregivers in treatment planning with patient consent 1
• Create crisis plan with emergency contacts and early warning signs of decompensation

10. Monitoring Schedule

Structured follow-up intervals:

• Weekly initially: Case manager home visits to assess adherence, symptoms, vital signs
• Monthly: Primary care for vital signs, medication review, PHQ-9, substance use screening
• Every 3 months: Metabolic panel (glucose, HbA1c, lipids, weight), renal function, CBC for anemia
• Every 6 months: Comprehensive psychiatric evaluation, functional assessment
• As needed: Urgent psychiatric evaluation for suicidal ideation, psychotic symptoms, or substance relapse

Common Pitfalls to Avoid

1. Fragmented care: Multiple specialists without coordination leads to medication interactions, duplicative testing, and treatment gaps 3
2. Undertreating cardiovascular disease: Psychiatric patients have 29-35% treatment gap for hypertension and 48-51% gap for hypercholesterolemia 4
3. Opioid prescribing: Given abuse history, avoid PRN opioids for breakthrough pain; use adjunctive therapies instead 1
4. Ignoring metabolic effects: Quetiapine requires ongoing metabolic monitoring; consider metformin if weight gain or glucose elevation occurs 10, 11
5. Subtherapeutic mood stabilizer: Lamotrigine 25mg is too low; titrate to therapeutic range 7
6. Polypharmacy without review: Regular medication reconciliation prevents drug-drug interactions and adverse effects 3

Risk Stratification

This patient is high-risk for:

• Hospital readmission (schizoaffective disorder with heart failure has lower odds of successful community discharge) 12
• Cardiovascular events (undertreated hypertension, heart failure, CKD)
• Psychiatric decompensation (history of suicidal ideation, substance abuse)
• Medication nonadherence (complex regimen, multiple comorbidities)
• Falls (psychotropic medications, cardiovascular medications, reduced mobility)

Intensive case management is justified and cost-effective for this high-risk profile 2.